NCT02796183View on ClinicalTrials.gov

The Efficacy of Subconjunctival Bevacizumab in Diabetic Macular Edema

NACompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

April 30, 2016

Study Completion Date

May 31, 2016

Conditions
Diabetic Macular Edema
Interventions
DRUG

Subconjunctival bevacizumab (Altuzan)

Subconjunctival injections of Altuzan 3.75mg were applied in order to eliminate the macular edema.

All Listed Sponsors
collaborator

Ondokuz Mayıs University

OTHER

lead

Neon Hospital

OTHER

NCT02796183 - The Efficacy of Subconjunctival Bevacizumab in Diabetic Macular Edema | Biotech Hunter | Biotech Hunter